Products
Preparation registered in Ukraine
N. Seredyuk, I.Vakalyuk, P. Zvonar, V. Mizyuk
Aterocard in treatment acute coronary syndromes without ST-segment elevation
Aterocard (clopidogrel) — a new preparation of the pharmaceutical domestic industry, which conforms to the well-known Plavix by its therapeutic activity. Clinical studies of Aterocard, carried out among the patients with acute coronary syndromes without ST-segment elevation had registered the following.
ADP-induced platelet aggregation index of those, who took Plavix (30 patients), has been reduced from 76,5±0,8% (before the treatment) to 29,5±0,3% (on the 14th day of the treatment) and to 19,5±0,2% (on the 28th day of the treatment), 22–35% is the norm.
ADP-induced platelet aggregation index of those, who took Aterocard (30 patients), has been reduced from 77,5±0,9% (before the treatment) to 31,5±0,4% (on the 14th day of the treatment) and to 20,0±0,4% (on the 24th day of the treatment). Both of the preparations are bioequivalent by efficiency, side-effect frequency, bearableness.
Key words: clopidogrel, acute coronary syndromes, plateletes aggregation.